Get started
Author

David Cocozziello

Observed name: Cocozziello, David
ORCID: 0000-0001-5497-6031
Observed ORCID: 0000-0001-5497-6031
OpenAlex ID: A5016658926
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors
2020 · Patrick D. Bhola, Eman Ahmed, et al. · Science Signaling · 68
Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers
2022 · Katrina L. Jackson, Roman V. Agafonov, et al. · Cancer Research · 40
CFT8634, a Clinical Stage BRD9 Bi DAC™ Degrader, Is Active in a Subset of Multiple Myeloma Cell Line Models and Synergistic When Combined with Pomalidomide
2023 · Laura L Poling, David Cocozziello, et al. · Blood · 23
A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination
2021 · Ellen F. Vieux, Roman V. Agafonov, et al. · SLAS DISCOVERY · 17
PDF
Abstract 2158: Preclinical evaluation of CFT1946 as a selective degrader of mutant BRAF for the treatment of BRAF driven cancers
2022 · Mathew E. Sowa, Bridget Kreger, et al. · Cancer Research · 12
Abstract 3425: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
2023 · Yanke Liang, Mathew E. Sowa, et al. · Cancer Research · 10
Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models
2021 · James A. Henderson, R. Jason Kirby, et al. · Cancer Research · 10
Abstract ND13: The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma
2022 · James A. Henderson, Scott J. Eron, et al. · Cancer Research · 5
Abstract 6046: CFT8634, a BRD9 BiDAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone
2024 · Laura L. Poling, David Cocozziello, et al. · Cancer Research · 2
Abstract ND05: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
2023 · Yanke Liang, Mathew E. Sowa, et al. · Cancer Research · 2
Abstract 1949: In vivo profiling of BET degraders establishes optimal pharmacological properties that showcase distinct biological differences from BET inhibitors
2020 · Brendon Ladd, David Cocozziello, et al. · Cancer Research
Works count: 13
Citation count: 189
H-index: 7
I10-index: 7
Year
Topic
Type